Table 2.
Summary of reports on the association of HLA-B*58:01 and allopurinol-induced severe cutaneous adverse reactions
| Ethnicity | Phenotypes | Patients, n (%) | Controls, n (%) | p value | OR (95% CI) |
|---|---|---|---|---|---|
| Han Chinese [47] | SJS/TEN | 51/51 (100) | 20/135 (15.0) | 4.7 × 10–24 | 580.3 (34.4–9,780.9) |
| European [50] | SJS/TEN | 14/27 (55) | 28/1822 (1.5) | < 1.0 × 10–6 | 80 (34–187) |
| Japanese [31] | SJS/TEN | 2/10 (20) | 6/986 (0.61) | < 1.0 × 10–4 | 40.83 (10.5–158.9) |
| Thai [48] | SJS/TEN | 27/27 (100) | 7/54 (13.0) | 1.6 × 10–13 | 348.3 (19.2–6,336.9) |
| Korean [49] | SJS/TEN, DRESS | 23/25 (92.0) | 6/57 (10.5) | 2.45 × 10–11 | 97.8 (18.3–521.5) |
| Portuguese [51] | SJS/TEN, DRESS | 16/25 (64) | 1/23 (4) | 5.9 × 10–9 | 39.11 (4.49–340.51) |
HLA, human leukocyte antigen; OR, odds ratio; CI, confidence interval; SJS, Stevens-Johnsons syndrome; TEN, toxic epidermal necrolysis; DRESS, drug reaction with eosinophilia and systemic symptoms.